What Researchers Did
Researchers reviewed records of 15 bleomycin-exposed patients who received hyperbaric oxygen therapy at a single center between 1979 and 2010 to assess its safety.
What They Found
The study found that hyperbaric oxygen was safely administered to 15 patients previously exposed to bleomycin, with a median age of 52 years (range 22-77). Patients received total bleomycin doses ranging from 40 to 225 u/m2, and HBO2 was primarily indicated for osteoradionecrosis (10 patients) or soft-tissue radionecrosis (3 patients).
What This Means for Canadian Patients
This study suggests that Canadian patients who have received bleomycin may safely undergo hyperbaric oxygen therapy for conditions such as osteoradionecrosis or soft-tissue radionecrosis. This could expand treatment options for these patients, who might otherwise be considered at high risk for pulmonary complications from supplemental oxygen.
Canadian Relevance
This study has no direct Canadian connection as it was conducted at a single center in the United States.
Study Limitations
This study is limited by its retrospective, single-center design and small sample size of 15 patients.